- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Lenalidomide
Lenalidomide is an immunomodulatory agent indicated for the treatment of transfusion‑dependent anemia due to low‑ or intermediate‑1‑risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality, multiple myeloma in combination with dexamethasone, and mantle cell lymphoma in patients who have relapsed or progressed after bortezomib and rituximab. It works by modulating the immune system, inhibiting the production of pro‑inflammatory cytokines, enhancing T‑cell and natural killer cell activity, and exerting direct antiproliferative effects on malignant plasma cells. Lenalidomide also inhibits angiogenesis. It is a structural analogue of thalidomide but with a different side‑effect profile and greater potency. The 10 mg capsule is used for dose titration and as a standard strength in several treatment regimens.
Usual adult dose: For multiple myeloma, the recommended starting dose is 25 mg once daily on Days 1 to 21 of a 28‑day cycle, in combination with dexamethasone. The 10 mg capsule is used for dose reductions or as a starting dose in patients with moderate renal impairment. For myelodysplastic syndromes with deletion 5q, the dose is 10 mg once daily on Days 1 to 21 of a 28‑day cycle; treatment continues until disease progression or intolerance. For mantle cell lymphoma, the dose is 25 mg once daily on Days 1 to 21 of a 28‑day cycle, with dose adjustments for toxicity. Capsules should be taken orally with water, with or without food, at approximately the same time each day. They must not be opened, crushed, or chewed. Renal dose adjustment is essential: in patients with creatinine clearance below 30 mL/min, the dose is 5 to 15 mg once daily depending on indication, and in end‑stage renal disease, 5 mg once daily or lower. If a dose is missed, the patient may take it if less than 12 hours have elapsed; otherwise, the missed dose should be skipped.
Dosage form: Hard gelatin capsules: 10 mg (blue‑green and pale yellow, imprinted with “10 mg” and “Rev” depending on brand). Available in blister packs of 21 or 28 capsules, dispensed only through a controlled distribution program.
Onset of action: For multiple myeloma, clinical response, measured by reduction in M‑protein and improvement in hematologic parameters, is typically observed within 1 to 3 months of starting therapy. For deletion 5q MDS, transfusion independence may be achieved after 2 to 4 months of treatment. Peak plasma concentrations occur 0.5 to 1.5 hours after oral dosing.
Duration of action: The elimination half‑life of lenalidomide is approximately 3 hours in patients with normal renal function, but the immunomodulatory and antineoplastic effects persist beyond the dosing interval because of downstream cellular changes. The standard cycle involves 21 days of treatment followed by 7 days off; this schedule maintains efficacy while allowing hematologic recovery.
Alcohol recommendation: Alcohol should be avoided or strictly limited during lenalidomide therapy. Alcohol can potentiate drowsiness and dizziness, increase gastrointestinal irritation, and may exacerbate hematologic toxicities such as neutropenia and thrombocytopenia. Patients with myeloma or MDS often have coexisting renal or hepatic impairment, and alcohol may worsen these conditions.
Most common side effects: Thrombocytopenia, neutropenia, anemia, fatigue, diarrhea, constipation, nausea, muscle cramps, rash, and peripheral edema. Venous thromboembolism (deep vein thrombosis and pulmonary embolism) is a serious risk, particularly when lenalidomide is combined with dexamethasone or other thrombogenic agents; prophylactic anticoagulation is recommended in many patients. Lenalidomide is highly teratogenic; it is absolutely contraindicated during pregnancy and in women of childbearing potential who cannot comply with mandatory pregnancy testing and effective contraception. In Canada, lenalidomide is available only through the RevAid controlled distribution program. Other serious adverse events include hepatotoxicity, severe cutaneous reactions such as Stevens‑Johnson syndrome, tumour lysis syndrome, and second primary malignancies, especially in the maintenance setting. Peripheral neuropathy is less common than with thalidomide but can occur. Patients should be monitored with complete blood counts at baseline, every 1 to 2 weeks for the first 2 months, and monthly thereafter, and renal function should be assessed regularly. Lenalidomide is not a cure and must be prescribed and supervised by a healthcare professional experienced in oncology or hematology.
Would you like to try Lenalidomide without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
